施贵宝(BMY)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

BMY 施贵宝

交易中 04-15 13:31:56 EDT

57.52

-0.56

-0.97%

最高58.16	最低57.23	成交量329.13万
今开58.04	昨收58.08	日振幅1.60%
总市值1,171亿	流通市值1,169亿	总股本20.36亿
成交额1.90亿	换手率0.16%	流通股本20.32亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"BMY","market":"US","secType":"STK","nameCN":"施贵宝","latestPrice":57.515,"timestamp":1776274315895,"preClose":58.08,"halted":0,"volume":3291286,"delay":0,"changeRate":-0.009727961432506848,"floatShares":2031646263,"shares":2035753027,"eps":3.46,"marketStatus":"交易中","change":-0.565,"latestTime":"04-15 13:31:56 EDT","open":58.04,"high":58.155,"low":57.225,"amount":189663067.76966402,"amplitude":0.016012,"askPrice":57.52,"askSize":503,"bidPrice":57.51,"bidSize":324,"shortable":3,"etf":0,"ttmEps":3.46,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1776283200000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":-18475200000,"exchange":"NYSE","adjPreClose":58.08,"dividendRate":0.043305,"preHourTrading":{"tag":"盘前","latestPrice":58.14,"preClose":58.08,"latestTime":"09:28 EDT","volume":2685,"amount":156115.842555,"timestamp":1776259704952,"change":0.06,"changeRate":0.001033,"amplitude":0.01188},"postHourTrading":{"tag":"盘后","latestPrice":57.8975,"preClose":58.08,"latestTime":"19:59 EDT","volume":659673,"amount":38313804.87584,"timestamp":1776211183510,"change":-0.1825,"changeRate":-0.003142,"amplitude":0.009857},"volumeRatio":0.597822,"impliedVol":0.3248,"impliedVolPercentile":0.512},"requestUrl":"/m/hq/s/BMY","defaultTab":"news","newsList":[{"id":"1142269574","title":"勃林格殷格翰：BioNTech将提供Pumitamig并担任Ib/II期研究监管申办方","url":"https://stock-news.laohu8.com/highlight/detail?id=1142269574","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1142269574?lang=zh_cn&edition=full","pubTime":"2026-04-09 20:14","pubTimestamp":1775736864,"startTime":"0","endTime":"0","summary":"勃林格殷格翰宣布，BioNTech公司将负责供应实验性药物Pumitamig，并作为Ib/II期临床研究的监管申办方。这项合作标志着双方在肿瘤治疗领域迈出关键一步。\n该研究将评估Pumitamig在特定患者群体中的安全性与有效性。通过整合资源与专业能力，两家企业旨在加速创新疗法的开发进程。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BJT1NW94.SGD","LU0306807586.USD","LU0882574055.USD","LU1430594728.SGD","IE00BJJMRZ35.SGD","LU1571399168.USD","LU1585245621.USD","LU0267386448.USD","BK4007","IE00B2B36J28.USD","BK4532","LU1670710661.SGD","LU2242646821.SGD","LU0306806265.USD","LU0114720955.EUR","LU1868836591.USD","BK4559","LU2125154935.USD","LU0096364046.USD","BK4581","IE0009355771.USD","BK4585","LU1670711040.USD","IE00BFTCPJ56.SGD","LU1093756168.USD","IE0002141913.USD","LU1718418525.SGD","LU0225771236.USD","LU0321505868.SGD","LU1989771016.USD","BMY","IE00BSNM7G36.USD","LU1670710588.SGD","LU1868837300.USD","LU1261432733.SGD","LU0868494617.USD","LU1868836914.USD","LU1074936037.SGD","LU0237698245.USD","LU1868837136.USD","LU0456855351.SGD","LU1323610961.USD","LU0321505439.SGD","LU1093756325.SGD","BK4534","LU2360032135.SGD","LU1032466523.USD","LU1883839398.USD","LU2125154778.USD","LU0225284248.USD","LU0985481810.HKD","LU0061475181.USD","LU1291159041.SGD","BK4588","LU1983299246.USD","LU1868836757.USD","LU2242652126.USD","LU2133065610.SGD","IE00BFXG1179.USD","LU1670711123.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1188985398","title":"勃林格殷格翰将评估Dll3靶向T细胞衔接器联合PD-L1/VEGF-A双特异性抗体治疗小细胞肺癌","url":"https://stock-news.laohu8.com/highlight/detail?id=1188985398","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1188985398?lang=zh_cn&edition=full","pubTime":"2026-04-09 20:13","pubTimestamp":1775736791,"startTime":"0","endTime":"0","summary":"勃林格殷格翰宣布将开展临床研究，评估其Dll3靶向T细胞衔接器与PD-L1/VEGF-A双特异性抗体联合疗法在小细胞肺癌治疗中的潜力。该联合方案旨在通过不同机制协同作用，为这种侵袭性肺癌患者探索新的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0225284248.USD","LU1670711040.USD","LU0237698245.USD","LU0985481810.HKD","LU1571399168.USD","IE00BFTCPJ56.SGD","LU1261432733.SGD","LU0321505439.SGD","LU1323610961.USD","IE0002141913.USD","LU1032466523.USD","LU1868836757.USD","IE0009355771.USD","LU1430594728.SGD","LU2360032135.SGD","BK4007","LU2125154935.USD","LU0456855351.SGD","BK4532","LU0096364046.USD","LU1868836914.USD","LU0225771236.USD","LU1670710661.SGD","LU1983299246.USD","IE00BJT1NW94.SGD","LU1718418525.SGD","LU0306806265.USD","LU2125154778.USD","BK4585","IE00BFXG1179.USD","LU0868494617.USD","LU1670710588.SGD","LU2242646821.SGD","BK4581","LU1093756325.SGD","LU2242652126.USD","LU1585245621.USD","BMY","LU0114720955.EUR","IE00BSNM7G36.USD","LU1093756168.USD","LU2133065610.SGD","LU0267386448.USD","LU1868837136.USD","BK4534","LU1291159041.SGD","LU0061475181.USD","LU1989771016.USD","IE00BJJMRZ35.SGD","LU0321505868.SGD","LU1883839398.USD","LU1074936037.SGD","LU1868837300.USD","LU0882574055.USD","LU1670711123.USD","BK4559","BK4588","LU0306807586.USD","IE00B2B36J28.USD","LU1868836591.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1111160887","title":"勃林格殷格翰：BioNTech与合作方保留各自资产完整权利，协议为互不排他性","url":"https://stock-news.laohu8.com/highlight/detail?id=1111160887","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1111160887?lang=zh_cn&edition=full","pubTime":"2026-04-09 20:07","pubTimestamp":1775736435,"startTime":"0","endTime":"0","summary":"根据最新协议条款，勃林格殷格翰宣布与BioNTech及其合作方达成的共识确认：各方将完全保留对自身资产的所有权及相关权益。\n此次签订的协议具有互不排他特性，意味着合作双方在保持各自知识产权独立性的同时，仍可与其他合作伙伴开展同类业务。该安排为各方在生物医药领域的持续创新与多元化合作预留了灵活空间。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BFXG1179.USD","BK4534","IE00BJT1NW94.SGD","BK4585","BK4532","LU0061475181.USD","LU1261432733.SGD","LU2360032135.SGD","LU0882574055.USD","LU2125154778.USD","LU2242652126.USD","LU1868836914.USD","LU1868837300.USD","LU1093756168.USD","LU1670711123.USD","IE00B2B36J28.USD","BK4559","LU0225771236.USD","LU1670710661.SGD","LU1868837136.USD","LU0306806265.USD","LU0114720955.EUR","LU0321505439.SGD","LU0868494617.USD","LU1291159041.SGD","LU0321505868.SGD","LU1093756325.SGD","LU1323610961.USD","IE00BJJMRZ35.SGD","BK4581","LU0237698245.USD","LU0306807586.USD","IE0002141913.USD","IE0009355771.USD","LU1868836591.USD","LU1074936037.SGD","LU1585245621.USD","IE00BFTCPJ56.SGD","LU2133065610.SGD","LU1670710588.SGD","LU1718418525.SGD","LU1032466523.USD","LU2125154935.USD","BMY","BK4007","BK4588","LU0456855351.SGD","LU0225284248.USD","LU0985481810.HKD","LU1430594728.SGD","LU0267386448.USD","LU0096364046.USD","LU1670711040.USD","LU1989771016.USD","IE00BSNM7G36.USD","LU1868836757.USD","LU2242646821.SGD","LU1983299246.USD","LU1571399168.USD","LU1883839398.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1143053047","title":"牛津生物治疗与施贵宝达成战略合作 共同研发实体瘤新一代T细胞衔接器","url":"https://stock-news.laohu8.com/highlight/detail?id=1143053047","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1143053047?lang=zh_cn&edition=full","pubTime":"2026-04-09 19:03","pubTimestamp":1775732595,"startTime":"0","endTime":"0","summary":"牛津生物治疗公司宣布与全球制药巨头施贵宝建立战略合作伙伴关系，双方将聚焦于实体瘤治疗领域，共同探索和开发新一代T细胞衔接器技术。这一合作旨在通过创新免疫疗法突破现有治疗瓶颈，为实体瘤患者提供更精准、高效的治疗方案。T细胞衔接器作为肿瘤免疫治疗的前沿方向，能够特异性激活患者自身免疫系统攻击癌细胞，在临床应用中展现出巨大潜力。此次强强联合将整合牛津生物治疗公司的专有抗体平台与施贵宝的全球研发资源，加速创新疗法的转化落地。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1585245621.USD","BK4534","BK4588","BK4007","IE0009355771.USD","LU0061475181.USD","LU1291159041.SGD","LU1323610961.USD","BK4532","LU2125154778.USD","LU2242646821.SGD","IE00BJT1NW94.SGD","IE00BSNM7G36.USD","LU1093756168.USD","LU1670711040.USD","LU1868836591.USD","LU0321505439.SGD","LU0225284248.USD","LU0985481810.HKD","LU1989771016.USD","IE00BFXG1179.USD","LU0114720955.EUR","BK4559","LU0267386448.USD","LU0237698245.USD","LU0306807586.USD","LU1571399168.USD","LU1868837136.USD","LU2133065610.SGD","LU2125154935.USD","BMY","LU1430594728.SGD","LU0882574055.USD","LU0456855351.SGD","LU1670710588.SGD","LU0096364046.USD","LU1074936037.SGD","LU0225771236.USD","IE00BFTCPJ56.SGD","LU0306806265.USD","LU1670711123.USD","LU0321505868.SGD","BK4581","IE0002141913.USD","LU1883839398.USD","IE00B2B36J28.USD","LU1983299246.USD","LU1718418525.SGD","LU1670710661.SGD","LU1868836914.USD","LU1868837300.USD","LU1261432733.SGD","LU1032466523.USD","LU2360032135.SGD","LU0868494617.USD","LU1093756325.SGD","BK4585","LU1868836757.USD","LU2242652126.USD","IE00BJJMRZ35.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626902114","title":"上海医药：公司挂牌转让上海施贵宝项目正有序推进中","url":"https://stock-news.laohu8.com/highlight/detail?id=2626902114","media":"每日经济新闻","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2626902114?lang=zh_cn&edition=full","pubTime":"2026-04-09 16:15","pubTimestamp":1775722547,"startTime":"0","endTime":"0","summary":"每经AI快讯，有投资者在投资者互动平台提问：董秘您好，请问公司挂牌转让所持上海施贵宝股份进展如何？公司今年对创新药研发计划投入由增加吗？上海医药（601607.SH）4月9日在投资者互动平台表示，公司挂牌转让上海施贵宝项目正有序推进中，相关交易进展公司会按照监管要求及时履行信息披露义务，请您继续关注公司公告。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604093699584342.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604093699584342.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0028","BK4534","BK4585","BK4532","BK1197","LU0061475181.USD","LU1261432733.SGD","LU0882574055.USD","LU2360032135.SGD","LU2242652126.USD","BK0020","LU1868836914.USD","LU1868837300.USD","BK0187","LU1670711123.USD","02607","IE00B2B36J28.USD","BK4559","LU0225771236.USD","LU1868837136.USD","BK0183","LU0114720955.EUR","LU0321505439.SGD","LU1291159041.SGD","BK0012","601607","LU0321505868.SGD","LU1093756325.SGD","LU1323610961.USD","IE00BJJMRZ35.SGD","LU0237698245.USD","BK0184","LU0306807586.USD","LU1074936037.SGD","LU1585245621.USD","IE00BFTCPJ56.SGD","LU2133065610.SGD","BK0188","BK0209","LU1032466523.USD","LU2125154935.USD","BMY","BK4588","LU0985481810.HKD","LU0267386448.USD","LU0096364046.USD","LU1670711040.USD","LU2242646821.SGD","LU1868836757.USD","LU1883839398.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623362213","title":"施贵宝(BMY.US)新药Camzyos三期临床告捷 有望成首款青少年罕见心脏病疗法","url":"https://stock-news.laohu8.com/highlight/detail?id=2623362213","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623362213?lang=zh_cn&edition=full","pubTime":"2026-03-30 10:04","pubTimestamp":1774836292,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，施贵宝于周日公布了其心脏病药物Camzyos三期临床试验的积极结果，该药物有望成为首款获批用于罹患罕见重症心脏病青少年群体的治疗方案。施贵宝表示，基于该药物已在成人患者中获批应用的基础，本次数据支持Camzyos拓展至青少年适应症的开发潜力。若该适应症最终获得监管机构批准，Camzyos将为这类患病青少年提供全新治疗选择，有望改善临床症状，并降低患者接受侵入性手术治疗的需求。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1421511.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"施贵宝(BMY.US)新药Camzyos三期临床告捷 有望成首款青少年罕见心脏病疗法","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1261432733.SGD","LU1323610961.USD","LU1670710661.SGD","LU1585245621.USD","IE0009355771.USD","LU0225771236.USD","BK4007","IE00BJJMRZ35.SGD","LU0061475181.USD","LU0114720955.EUR","LU0306806265.USD","LU0456855351.SGD","LU0985481810.HKD","LU1093756325.SGD","LU1670711040.USD","LU0321505439.SGD","LU1868836914.USD","BK4585","LU1571399168.USD","LU1868836757.USD","LU0868494617.USD","BMY","LU1868836591.USD","IE00BFXG1179.USD","LU1291159041.SGD","IE00BSNM7G36.USD","LU1074936037.SGD","LU2125154935.USD","IE0002141913.USD","LU2360032135.SGD","LU2125154778.USD","IE00B2B36J28.USD","LU1430594728.SGD","LU0321505868.SGD","LU0306807586.USD","LU0882574055.USD","LU1670711123.USD","LU2242646821.SGD","LU0237698245.USD","LU1883839398.USD","LU0096364046.USD","LU1032466523.USD","LU0225284248.USD","LU2242652126.USD","IE00BFTCPJ56.SGD","LU0267386448.USD","LU1718418525.SGD","BK4532","LU1868837136.USD","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1153187319","title":"施贵宝：Camzyos在青少年中的安全性特征与成人群体相似","url":"https://stock-news.laohu8.com/highlight/detail?id=1153187319","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1153187319?lang=zh_cn&edition=full","pubTime":"2026-03-29 23:47","pubTimestamp":1774799230,"startTime":"0","endTime":"0","summary":"施贵宝公司公布的研究数据显示，其药物Camzyos在青少年患者群体中展现出的安全性特征，与已在成人患者中确立的安全性数据基本一致。\n这一发现为Camzyos在更广泛年龄层患者中的应用提供了重要的安全依据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0882574055.USD","BMY","LU1571399168.USD","BK4585","LU2360032135.SGD","LU1868836591.USD","LU0306807586.USD","BK4534","LU0225284248.USD","LU1868837136.USD","IE00BJT1NW94.SGD","LU1868837300.USD","BK4007","IE00BJJMRZ35.SGD","BK4559","LU0985481810.HKD","LU0868494617.USD","LU1670711123.USD","BK4581","BK4532","LU0267386448.USD","LU1868836757.USD","IE0002141913.USD","IE0009355771.USD","LU1868836914.USD","LU1670711040.USD","LU0237698245.USD","LU1032466523.USD","LU0225771236.USD","LU1261432733.SGD","BK4588","IE00BFXG1179.USD","LU0456855351.SGD","LU1291159041.SGD","LU0306806265.USD","LU1718418525.SGD","LU2242646821.SGD","LU1093756168.USD","LU0321505439.SGD","LU2125154778.USD","LU0321505868.SGD","LU1989771016.USD","LU1430594728.SGD","LU0114720955.EUR","LU0096364046.USD","LU1323610961.USD","LU2125154935.USD","LU1883839398.USD","IE00BSNM7G36.USD","LU1670710661.SGD","LU1093756325.SGD","LU2133065610.SGD","LU1670710588.SGD","LU2242652126.USD","LU1074936037.SGD","LU0061475181.USD","LU1585245621.USD","IE00BFTCPJ56.SGD","IE00B2B36J28.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1142677348","title":"施贵宝SCOUT-HCM试验达到主要终点：第28周左心室流出道压差显著降低","url":"https://stock-news.laohu8.com/highlight/detail?id=1142677348","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1142677348?lang=zh_cn&edition=full","pubTime":"2026-03-29 23:46","pubTimestamp":1774799171,"startTime":"0","endTime":"0","summary":"施贵宝公司宣布，其SCOUT-HCM临床试验在第28周时成功达到主要研究终点，数据显示患者左心室流出道压差实现显著降低。\n该结果验证了实验性疗法对梗阻性肥厚型心肌病的治疗潜力，为后续研发提供了关键数据支持。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4534","LU0114720955.EUR","LU0225284248.USD","LU1093756168.USD","LU1670710661.SGD","BK4588","LU1585245621.USD","IE00BSNM7G36.USD","LU1261432733.SGD","BK4585","BK4007","LU0225771236.USD","LU0061475181.USD","LU2242646821.SGD","LU2360032135.SGD","IE00BFTCPJ56.SGD","IE0002141913.USD","BK4532","LU0306807586.USD","LU1670711040.USD","LU1670710588.SGD","LU1883839398.USD","LU1323610961.USD","LU1074936037.SGD","BK4581","LU0456855351.SGD","LU0267386448.USD","LU2133065610.SGD","LU1291159041.SGD","LU1718418525.SGD","LU1868836757.USD","LU1868836591.USD","LU1868836914.USD","LU0096364046.USD","IE00B2B36J28.USD","BK4559","LU0237698245.USD","LU1989771016.USD","LU1430594728.SGD","LU1868837300.USD","BMY","LU0985481810.HKD","LU0321505439.SGD","LU2242652126.USD","LU0321505868.SGD","IE00BJT1NW94.SGD","LU1093756325.SGD","IE0009355771.USD","IE00BFXG1179.USD","LU1571399168.USD","LU1868837136.USD","LU0868494617.USD","LU1670711123.USD","LU0882574055.USD","LU2125154935.USD","LU0306806265.USD","IE00BJJMRZ35.SGD","LU2125154778.USD","LU1032466523.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1100294344","title":"施贵宝公布3期SCOUT-HCM试验积极结果：Camzyos（Mavacamten）在青少年症状性梗阻性肥厚型心肌病患者中展现显著疗效与安全性","url":"https://stock-news.laohu8.com/highlight/detail?id=1100294344","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1100294344?lang=zh_cn&edition=full","pubTime":"2026-03-29 23:45","pubTimestamp":1774799114,"startTime":"0","endTime":"0","summary":"施贵宝近日公布了其3期SCOUT-HCM临床试验的积极数据，该研究评估了Camzyos（通用名：Mavacamten）在青少年症状性梗阻性肥厚型心肌病患者中的疗效与安全性。试验结果证实，该药物在此患者群体中表现出显著的治疗效果和良好的安全特性。\n梗阻性肥厚型心肌病是一种心肌异常增厚的慢性疾病，常导致心脏血流受阻。此次针对青少年患者的临床试验达到主要终点，为这一难治性疾病提供了新的治疗希望。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1868837136.USD","LU0321505439.SGD","LU0456855351.SGD","BK4588","BK4532","LU0061475181.USD","LU1868836914.USD","LU0306807586.USD","LU1430594728.SGD","LU1883839398.USD","LU0114720955.EUR","BK4581","LU1718418525.SGD","LU1868836591.USD","LU2360032135.SGD","LU0096364046.USD","LU0237698245.USD","BK4559","LU0868494617.USD","LU0985481810.HKD","LU1670710661.SGD","LU2242652126.USD","LU2242646821.SGD","LU0267386448.USD","LU0225771236.USD","IE00BJJMRZ35.SGD","BK4534","IE0009355771.USD","LU0321505868.SGD","LU1032466523.USD","IE0002141913.USD","LU1093756325.SGD","LU1074936037.SGD","LU1323610961.USD","LU1093756168.USD","IE00B2B36J28.USD","LU1261432733.SGD","LU1585245621.USD","BK4007","BMY","LU0306806265.USD","LU1291159041.SGD","IE00BFXG1179.USD","LU0225284248.USD","LU1868837300.USD","IE00BJT1NW94.SGD","LU0882574055.USD","IE00BFTCPJ56.SGD","LU2125154935.USD","LU2133065610.SGD","BK4585","LU1989771016.USD","LU1868836757.USD","LU2125154778.USD","LU1670710588.SGD","LU1571399168.USD","IE00BSNM7G36.USD","LU1670711040.USD","LU1670711123.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1128671176","title":"施贵宝：开放标签门诊转换研究显示，从口服非典型抗精神病药过渡至Cobenfy期间症状稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1128671176","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1128671176?lang=zh_cn&edition=full","pubTime":"2026-03-28 19:14","pubTimestamp":1774696452,"startTime":"0","endTime":"0","summary":"一项由施贵宝开展的开放标签门诊转换研究证实，患者在从口服非典型抗精神病药物转换至Cobenfy的治疗过程中，其精神症状能够保持稳定。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0306807586.USD","LU1291159041.SGD","LU1883839398.USD","LU1868836591.USD","IE0009355771.USD","LU2125154935.USD","LU1074936037.SGD","LU1323610961.USD","LU2125154778.USD","LU1670711040.USD","LU1868837300.USD","IE00BFXG1179.USD","IE0002141913.USD","BK4534","IE00BFTCPJ56.SGD","BK4588","BK4007","BK4585","LU0985481810.HKD","LU1868836914.USD","LU1868837136.USD","LU0096364046.USD","BK4581","IE00BJJMRZ35.SGD","BMY","LU2133065610.SGD","LU2242652126.USD","BK4559","LU1670711123.USD","LU0456855351.SGD","LU1718418525.SGD","LU1585245621.USD","LU1670710661.SGD","IE00BJT1NW94.SGD","LU1093756168.USD","LU0882574055.USD","LU1032466523.USD","LU1670710588.SGD","LU1261432733.SGD","LU1571399168.USD","LU1430594728.SGD","IE00B2B36J28.USD","LU0225284248.USD","BK4532","LU0225771236.USD","LU0237698245.USD","LU0267386448.USD","LU1868836757.USD","LU1989771016.USD","LU2360032135.SGD","LU0321505439.SGD","LU0061475181.USD","LU2242646821.SGD","LU0306806265.USD","LU1093756325.SGD","LU0114720955.EUR","LU0321505868.SGD","LU0868494617.USD","IE00BSNM7G36.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1148811954","title":"施贵宝公布Camzyos新数据，巩固其在梗阻性肥厚型心肌病领域领导地位","url":"https://stock-news.laohu8.com/highlight/detail?id=1148811954","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1148811954?lang=zh_cn&edition=full","pubTime":"2026-03-23 19:01","pubTimestamp":1774263670,"startTime":"0","endTime":"0","summary":"在2026年美国心脏病学会年度科学会议暨博览会（ACC.26）上，施贵宝公布了其药物Camzyos（Mavacamten）的最新数据。这些新数据进一步强化了该公司在梗阻性肥厚型心肌病治疗领域的领先地位。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1074936037.SGD","LU1323610961.USD","BK4559","IE00BFTCPJ56.SGD","IE0009355771.USD","LU1291159041.SGD","BK4534","IE00BSNM7G36.USD","LU1670710661.SGD","LU1032466523.USD","BK4585","LU2133065610.SGD","LU0114720955.EUR","LU1093756168.USD","LU2125154935.USD","BK4007","LU0321505439.SGD","BK4581","LU1261432733.SGD","LU0096364046.USD","LU0225284248.USD","LU1868837300.USD","LU0306807586.USD","LU1571399168.USD","IE00B2B36J28.USD","LU0237698245.USD","LU1670710588.SGD","LU1093756325.SGD","LU1868836914.USD","BK4588","LU0267386448.USD","LU0985481810.HKD","LU0882574055.USD","IE0002141913.USD","IE00BJJMRZ35.SGD","LU2242646821.SGD","LU0321505868.SGD","LU1868836757.USD","IE00BFXG1179.USD","LU2242652126.USD","BMY","LU1868836591.USD","BK4532","LU0306806265.USD","LU0456855351.SGD","LU1670711123.USD","LU1868837136.USD","IE00BJT1NW94.SGD","LU1718418525.SGD","LU1585245621.USD","LU2360032135.SGD","LU1989771016.USD","LU0061475181.USD","LU1883839398.USD","LU0225771236.USD","LU2125154778.USD","LU1430594728.SGD","LU1670711040.USD","LU0868494617.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1197973313","title":"FDA授予纳武利尤单抗传统批准 用于自体造血干细胞移植及维布妥昔单抗治疗后复发或难治性经典霍奇金淋巴瘤成人患者","url":"https://stock-news.laohu8.com/highlight/detail?id=1197973313","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1197973313?lang=zh_cn&edition=full","pubTime":"2026-03-21 00:16","pubTimestamp":1774023393,"startTime":"0","endTime":"0","summary":"美国食品药品监督管理局（FDA）已正式授予纳武利尤单抗（Nivolumab）传统批准，该药物适用于曾接受自体造血干细胞移植（HSCT）及维布妥昔单抗（Brentuximab Vedotin）治疗后，病情出现复发或难治性的经典霍奇金淋巴瘤（cHL）成年患者。\n此次传统批准的授予，标志着该免疫疗法在治疗这一特定患者群体方面获得了监管机构的全面认可。纳武利尤单抗由施贵宝（Bristol-Myers Squibb）研发，是一种PD-1抑制剂，能够通过激活人体自身的免疫系统来攻击癌细胞。\n这一决定为患有复发或难治性经典霍奇金淋巴瘤的成人提供了新的重要治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4534","LU0114720955.EUR","LU0225284248.USD","LU1093756168.USD","LU1670710661.SGD","BK4588","LU1585245621.USD","IE00BSNM7G36.USD","LU1261432733.SGD","BK4585","BK4007","LU0225771236.USD","LU0061475181.USD","LU2242646821.SGD","LU2360032135.SGD","IE00BFTCPJ56.SGD","IE0002141913.USD","BK4532","LU0306807586.USD","LU1670711040.USD","LU1670710588.SGD","LU1883839398.USD","LU1323610961.USD","LU1074936037.SGD","BK4581","LU0456855351.SGD","LU0267386448.USD","LU2133065610.SGD","LU1291159041.SGD","LU1718418525.SGD","LU1868836757.USD","LU1868836591.USD","LU1868836914.USD","LU0096364046.USD","IE00B2B36J28.USD","BK4559","LU0237698245.USD","LU1989771016.USD","LU1430594728.SGD","LU1868837300.USD","BMY","LU0985481810.HKD","LU0321505439.SGD","LU2242652126.USD","LU0321505868.SGD","IE00BJT1NW94.SGD","LU1093756325.SGD","IE0009355771.USD","IE00BFXG1179.USD","LU1571399168.USD","LU1868837136.USD","LU0868494617.USD","LU1670711123.USD","LU0882574055.USD","LU2125154935.USD","LU0306806265.USD","IE00BJJMRZ35.SGD","LU2125154778.USD","LU1032466523.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620238733","title":"杰富瑞上调施贵宝目标价至70美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2620238733","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620238733?lang=zh_cn&edition=full","pubTime":"2026-03-18 15:48","pubTimestamp":1773820082,"startTime":"0","endTime":"0","summary":"杰富瑞将施贵宝的目标价从68美元上调至70美元，维持“买入”评级。(格隆汇)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260318/32078061.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BMY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619115423","title":"FDA批准百时美施贵宝(BMY.US)TYK2抑制剂氘可来昔替尼治疗活动性银屑病关节炎成人患者","url":"https://stock-news.laohu8.com/highlight/detail?id=2619115423","media":"智通财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619115423?lang=zh_cn&edition=full","pubTime":"2026-03-13 07:00","pubTimestamp":1773356416,"startTime":"0","endTime":"0","summary":"百时美施贵宝(BMY.US)宣布，美国食品药品监督管理局(FDA)已批准颂狄多®(氘可来昔替尼)用于治疗活动性银屑病关节炎(PsA)成人患者。","market":"us","thumbnail":"https://img.zhitongcaijing.com/image/20260313/20260313065958_28723.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20260313/20260313065958_28723.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1413366.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK4534","BK4581","IE00BFXG1179.USD","BK4007","IE00BJT1NW94.SGD","LU2125154935.USD","LU1585245621.USD","LU1093756325.SGD","LU0985481810.HKD","LU0267386448.USD","LU1868836591.USD","LU2242652126.USD","BK4532","LU0306806265.USD","LU1032466523.USD","LU0306807586.USD","LU0225771236.USD","LU1670710588.SGD","LU1718418525.SGD","IE00B2B36J28.USD","LU2360032135.SGD","IE0009355771.USD","LU1868837300.USD","LABU","LU1868836757.USD","LU0225284248.USD","LU1323610961.USD","IE00BFTCPJ56.SGD","IE00BSNM7G36.USD","BMY","BK4588","LU1883839398.USD","IE0002141913.USD","LU1868836914.USD","LU1670710661.SGD","BK4559","LU1670711123.USD","LU1261432733.SGD","LU0882574055.USD","LU2125154778.USD","LU0114720955.EUR","LU0456855351.SGD","LU0868494617.USD","LU1989771016.USD","LU1868837136.USD","LU0061475181.USD","LU0321505439.SGD","LU1093756168.USD","LU0237698245.USD","LU1430594728.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1103858181","title":"施贵宝公布口服Mezigdomide治疗复发或难治性多发性骨髓瘤的Successor-2研究积极3期结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1103858181","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1103858181?lang=zh_cn&edition=full","pubTime":"2026-03-09 19:00","pubTimestamp":1773054013,"startTime":"0","endTime":"0","summary":"施贵宝宣布，其口服药物Mezigdomide针对复发或难治性多发性骨髓瘤的Successor-2研究取得积极3期临床试验结果。该研究达到了主要终点，显示患者无进展生存期显著改善。\n安全性方面，Mezigdomide表现出可控的安全性特征，与既往研究一致。详细数据将在即将召开的医学会议上公布。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0096364046.USD","BMY","LU2125154778.USD","LU1670710661.SGD","LU0306806265.USD","LU1323610961.USD","LU1883839398.USD","LU1430594728.SGD","LU1670711040.USD","LU1291159041.SGD","LU0321505439.SGD","IE0009355771.USD","LU0868494617.USD","LU2133065610.SGD","LU1074936037.SGD","IE00BFXG1179.USD","LU2360032135.SGD","IE00BJJMRZ35.SGD","LU0225771236.USD","LU2242652126.USD","LU0114720955.EUR","LU1261432733.SGD","LU1989771016.USD","LU0882574055.USD","LU2242646821.SGD","BK4588","LU1868836591.USD","LU1093756168.USD","BK4581","BK4534","BK4585","LU1718418525.SGD","LU1868837136.USD","IE0002141913.USD","LU0225284248.USD","LU0321505868.SGD","IE00BJT1NW94.SGD","LU0456855351.SGD","LU1670711123.USD","BK4532","LU1670710588.SGD","LU1093756325.SGD","IE00B2B36J28.USD","LU1571399168.USD","LU1032466523.USD","LU2125154935.USD","LU1868836757.USD","IE00BSNM7G36.USD","IE00BFTCPJ56.SGD","LU0061475181.USD","LU1868837300.USD","LU1585245621.USD","LU0985481810.HKD","LU0306807586.USD","BK4007","LU0267386448.USD","LU0237698245.USD","LU1868836914.USD","BK4559"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136008921","title":"施贵宝旗下Mezikd在RRMM治疗中展现无进展生存期显著改善","url":"https://stock-news.laohu8.com/highlight/detail?id=1136008921","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1136008921?lang=zh_cn&edition=full","pubTime":"2026-03-09 19:00","pubTimestamp":1773054012,"startTime":"0","endTime":"0","summary":"施贵宝公司近日公布，其研发的药物Mezikd在针对复发或难治性多发性骨髓瘤（RRMM）的临床试验中，取得了无进展生存期（PFS）的显著改善。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1585245621.USD","BK4534","BK4588","BK4007","IE0009355771.USD","LU0061475181.USD","LU1291159041.SGD","LU1323610961.USD","BK4532","LU2125154778.USD","LU2242646821.SGD","IE00BJT1NW94.SGD","IE00BSNM7G36.USD","LU1093756168.USD","LU1670711040.USD","LU1868836591.USD","LU0321505439.SGD","LU0225284248.USD","LU0985481810.HKD","LU1989771016.USD","IE00BFXG1179.USD","LU0114720955.EUR","BK4559","LU0267386448.USD","LU0237698245.USD","LU0306807586.USD","LU1571399168.USD","LU1868837136.USD","LU2133065610.SGD","LU2125154935.USD","BMY","LU1430594728.SGD","LU0882574055.USD","LU0456855351.SGD","LU1670710588.SGD","LU0096364046.USD","LU1074936037.SGD","LU0225771236.USD","IE00BFTCPJ56.SGD","LU0306806265.USD","LU1670711123.USD","LU0321505868.SGD","BK4581","IE0002141913.USD","LU1883839398.USD","IE00B2B36J28.USD","LU1718418525.SGD","LU1670710661.SGD","LU1868836914.USD","LU1868837300.USD","LU1261432733.SGD","LU1032466523.USD","LU2360032135.SGD","LU0868494617.USD","LU1093756325.SGD","BK4585","LU1868836757.USD","LU2242652126.USD","IE00BJJMRZ35.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1156464014","title":"美国FDA批准施贵宝Sotyktu®（Deucravacitinib）用于治疗活动性银屑病关节炎成人患者","url":"https://stock-news.laohu8.com/highlight/detail?id=1156464014","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1156464014?lang=zh_cn&edition=full","pubTime":"2026-03-07 10:59","pubTimestamp":1772852352,"startTime":"0","endTime":"0","summary":"美国食品药品监督管理局（FDA）已正式批准施贵宝公司研发的Sotyktu®（通用名：Deucravacitinib）用于治疗成人活动性银屑病关节炎。这一决定为患者提供了一种全新的口服治疗选择，有望显著改善其生活质量。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BFXG1179.USD","BK4585","BK4581","LU1868836757.USD","LU2133065610.SGD","LU1430594728.SGD","LU0061475181.USD","LU0306807586.USD","LU1670710588.SGD","LU1585245621.USD","LU0306806265.USD","LU1868837300.USD","LU2360032135.SGD","LU1718418525.SGD","BK4588","LU1670710661.SGD","LU1093756168.USD","LU0456855351.SGD","BMY","LU0267386448.USD","LU0985481810.HKD","LU1883839398.USD","LU1074936037.SGD","LU0114720955.EUR","LU0225284248.USD","LU0225771236.USD","LU1291159041.SGD","IE00BSNM7G36.USD","LU1989771016.USD","LU0321505439.SGD","LU0237698245.USD","LU1093756325.SGD","LU1670711123.USD","LU1868837136.USD","BK4007","LU0096364046.USD","LU0321505868.SGD","LU1670711040.USD","BK4532","LU1868836591.USD","LU2125154778.USD","LU1323610961.USD","IE00BJJMRZ35.SGD","LU0882574055.USD","LU1032466523.USD","LU1261432733.SGD","BK4534","LU0868494617.USD","IE0002141913.USD","IE00BFTCPJ56.SGD","IE00BJT1NW94.SGD","LU1868836914.USD","LU1571399168.USD","LU2125154935.USD","IE0009355771.USD","IE00B2B36J28.USD","LU2242646821.SGD","LU2242652126.USD","BK4559"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617304590","title":"上海医药这次割肉有点狠","url":"https://stock-news.laohu8.com/highlight/detail?id=2617304590","media":"指针Point","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617304590?lang=zh_cn&edition=full","pubTime":"2026-03-05 08:31","pubTimestamp":1772670705,"startTime":"0","endTime":"0","summary":"作者|黄宇晨编辑| 方  乔近期，上海医药对外发布公告称，其将以不低于10.23亿元人民币的底价，借助公开挂牌的途径，转让持有的中美上海施贵宝制药有限公司30%的股权。对上海医药来说，出售中美施贵宝股权，是主动调整资产，也反映出其正面临结构性压力。在此情况下，上海医药主动叫停效益差的项目。与此同时，上海医药正加速推进创新药布局。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260305085909a44d3268&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260305085909a44d3268&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4585","IE00BJJMRZ35.SGD","LU0882574055.USD","LU0985481810.HKD","IE00BJT1NW94.SGD","LU1868837136.USD","LU0061475181.USD","LU0267386448.USD","LU0321505439.SGD","LU0868494617.USD","LU1032466523.USD","LU1868836757.USD","LU2125154935.USD","BK4007","BMY","LU1868836914.USD","LU0456855351.SGD","IE00BSNM7G36.USD","LU0225284248.USD","BMS","LU1868837300.USD","IE0002141913.USD","LU1074936037.SGD","LU1718418525.SGD","LU2133065610.SGD","LU1670710588.SGD","IE00BFTCPJ56.SGD","LU2242646821.SGD","LU0237698245.USD","BK4532","LU0114720955.EUR","LU1291159041.SGD","LU1670711040.USD","BK4559","LU0306807586.USD","LU2242652126.USD","LU0225771236.USD","LU1093756325.SGD","LU1670711123.USD","LU1883839398.USD","LU0096364046.USD","LU0321505868.SGD","LU1430594728.SGD","LU2125154778.USD","BK4534","BK4581","LU1571399168.USD","LU1868836591.USD","BK4588","LU1261432733.SGD","02607"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2613799350","title":"Piper Sandler上调施贵宝目标价至75美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2613799350","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2613799350?lang=zh_cn&edition=full","pubTime":"2026-02-24 17:07","pubTimestamp":1771924028,"startTime":"0","endTime":"0","summary":"Piper Sandler将施贵宝的目标价从66美元上调至75美元，维持“增持”评级。(格隆汇)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260224/32023666.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BMY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1103835253","title":"施贵宝公布Luspatercept治疗成人α-地中海贫血注册性II期研究积极顶线结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1103835253","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1103835253?lang=zh_cn&edition=full","pubTime":"2026-02-23 19:59","pubTimestamp":1771847954,"startTime":"0","endTime":"0","summary":"施贵宝宣布，其针对成人α-地中海贫血患者开展的Luspatercept注册性II期临床试验获得积极顶线结果。该研究达到了主要终点，显示Luspatercept在提升血红蛋白水平方面具有显著疗效。安全性数据与既往研究一致，未发现新的安全隐患。\n这一突破性进展为α-地中海贫血患者带来了新的治疗希望。Luspatercept作为首个在该适应症中显示潜力的创新疗法，有望填补当前治疗领域的空白。公司计划与监管机构讨论后续注册路径，加速推动该药物惠及全球患者。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0321505868.SGD","LU1868836757.USD","LU1261432733.SGD","LU1571399168.USD","LU0882574055.USD","LU1868836591.USD","LU1032466523.USD","LU0096364046.USD","LU1074936037.SGD","BK4007","LU2242652126.USD","LU0237698245.USD","LU1868836914.USD","BK4559","LU1585245621.USD","LU0306807586.USD","LU2242646821.SGD","LU1670711040.USD","LU2133065610.SGD","BK4588","IE00BJT1NW94.SGD","LU1291159041.SGD","LU1430594728.SGD","LU0456855351.SGD","LU0868494617.USD","BMY","LU0306806265.USD","LU1670710661.SGD","LU1868837136.USD","IE00BFXG1179.USD","LU2360032135.SGD","LU2125154778.USD","LU1323610961.USD","LU1883839398.USD","LU1868837300.USD","BK4532","BK4581","LU1718418525.SGD","LU2125154935.USD","BK4585","LU0985481810.HKD","IE0009355771.USD","LU1989771016.USD","LU0114720955.EUR","LU1670710588.SGD","IE00BSNM7G36.USD","LU0225771236.USD","IE00B2B36J28.USD","LU0225284248.USD","IE00BJJMRZ35.SGD","LU0321505439.SGD","LU1093756168.USD","IE0002141913.USD","LU1093756325.SGD","LU1670711123.USD","IE00BFTCPJ56.SGD","LU0267386448.USD","BK4534","LU0061475181.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.bms.com","stockEarnings":[{"period":"1week","weight":0.0071},{"period":"1month","weight":-0.0169},{"period":"3month","weight":0.0186},{"period":"6month","weight":0.3386},{"period":"1year","weight":0.1313},{"period":"ytd","weight":0.0768}],"compareEarnings":[{"period":"1week","weight":0.0535},{"period":"1month","weight":0.0486},{"period":"3month","weight":0.0059},{"period":"6month","weight":0.0512},{"period":"1year","weight":0.2881},{"period":"ytd","weight":0.0184}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"百时美施贵宝公司于1933年8月在美国德拉瓦州注册成立，源自于1887年在纽约创办的企业，并在1989年因合并而重命名。作为一家生物制药公司，百时美施贵宝专注于创新药物的发现、开发、许可、生产、营销和销售，以对抗严重疾病。公司的战略方法结合了大型制药公司的资源和规模，以及生物技术行业特有的灵活性和创新重点。百时美施贵宝优先关注肿瘤学、血液学、免疫学、心血管和神经科学等领域的变革性药物，旨在提供长期价值和竞争优势。作为全球研究型制药公司，百时美施贵宝的产品在全球范围内销售，服务于包括批发商、分销商和特药药房在内的多种实体，并在多个国家保持着重要的生产运营。","yearOnYearQuotes":[{"month":1,"riseRate":0.478261,"avgChangeRate":-0.011323},{"month":2,"riseRate":0.565217,"avgChangeRate":0.011855},{"month":3,"riseRate":0.630435,"avgChangeRate":0.007963},{"month":4,"riseRate":0.468085,"avgChangeRate":-0.006689},{"month":5,"riseRate":0.565217,"avgChangeRate":0.002647},{"month":6,"riseRate":0.608696,"avgChangeRate":0.009417},{"month":7,"riseRate":0.413043,"avgChangeRate":-0.001733},{"month":8,"riseRate":0.521739,"avgChangeRate":-0.001022},{"month":9,"riseRate":0.521739,"avgChangeRate":0.00993},{"month":10,"riseRate":0.586957,"avgChangeRate":0.025121},{"month":11,"riseRate":0.630435,"avgChangeRate":0.022318},{"month":12,"riseRate":0.630435,"avgChangeRate":0.022265}],"exchange":"NYSE","name":"施贵宝","nameEN":"Bristol-Myers Squibb"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.41.0","shortVersion":"4.41.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"施贵宝(BMY)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供施贵宝(BMY)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"施贵宝,BMY,施贵宝股票,施贵宝股票老虎,施贵宝股票老虎国际,施贵宝行情,施贵宝股票行情,施贵宝股价,施贵宝股市,施贵宝股票价格,施贵宝股票交易,施贵宝股票购买,施贵宝股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"施贵宝(BMY)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供施贵宝(BMY)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}